Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.98 |
| ▸ | MEN1 | O00255 | 4/20 | 0.98 |
| ▸ | LMNA | P02545 | 4/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.98 |
| ▸ | NPC1 | O15118 | 4/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.98 |
| ▸ | CASP1 | P29466 | 4/20 | 0.98 |
| ▸ | CASP7 | P55210 | 4/20 | 0.98 |
| ▸ | RAB9A | P51151 | 3/20 | 0.98 |
| ▸ | TP53 | P04637 | 2/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.98 |
| ▸ | ESR1 | P03372 | 1/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.98 |
| ▸ | TSHR | P16473 | 1/20 | 0.98 |
| ▸ | HTT | P42858 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 4/20 | 0.80 |
| ▸ | POLB | P06746 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3918724 | 0.89 | HPGD (1.00) | HPGDHSD17B10MEN1LMNAKMT2A | |
| SCHEMBL12443131 | 0.82 | TP53 (0.80) | HPGDHSD17B10MEN1LMNAKMT2A | |
| SCHEMBL3922433 | 0.82 | MEN1 (0.82) | HPGDHSD17B10MEN1LMNAKMT2A | |
| SCHEMBL21067808 | 0.82 | KIF11 (1.00) | HPGDHSD17B10MEN1LMNAKMT2A | |
| SCHEMBL4150336 | 0.81 | SMN1; SMN2 (0.71) | HPGDHSD17B10MEN1LMNAKMT2A | |
| SCHEMBL3128198 | 0.81 | FLT3 (1.00) | HPGDMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL24489158 | 0.81 | CFTR (0.74) | HPGDHSD17B10MEN1LMNAKMT2A | |
| SCHEMBL24490597 | 0.81 | CFTR (1.00) | HPGDHSD17B10MEN1LMNAKMT2A | |
| SCHEMBL8289672 | 0.80 | FLT3 (0.97) | HPGDMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL5457818 | 0.79 | FLT3 (1.00) | MEN1KMT2ASMN1; SMN2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298842-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | PATO JANOS | 2009-12-03 | — | — | US | claimed |
| US-20090018149-A1 | 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections | AXXIMA PHARMACEUTICALS AG (DE) | 2009-01-15 | — | — | US | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| EP-1670804-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC Biotech AG (DE) | 2006-06-21 | — | — | EP | claimed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | claimed |
| US-20040171603-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | VICHEM CHEMIE KFT (HU) | 2004-09-02 | — | — | US | claimed |
| EP-1294707-A2 | THIOPHENE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2003-03-26 | — | — | EP | claimed |
| WO-2001098290-A2 | THIOPHENE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2001-12-27 | — | — | WO | claimed |
| US-20090298842-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | PATO JANOS | 2009-12-03 | — | — | US | disclosed |
| US-20090018149-A1 | 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections | AXXIMA PHARMACEUTICALS AG (DE) | 2009-01-15 | — | — | US | disclosed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
| EP-1670804-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC Biotech AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | disclosed |
| US-20040171603-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | VICHEM CHEMIE KFT (HU) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298842-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | PKLR, MASTL, BPGM | HPGD 964/4885HSD17B10 4508/4885MEN1 2985/4885 |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | HPGD 2361/4885HSD17B10 635/4885MEN1 2891/4885 |
| US-20040171603-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | PKLR, PKN1, PKMYT1 | HPGD 852/4885HSD17B10 4186/4885MEN1 2405/4885 |
| US-20090018149-A1 | 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections | STK4, SBK3, STK17B | HPGD 2459/4885HSD17B10 2635/4885MEN1 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.